Insider Selling: Health Catalyst, Inc. (NASDAQ:HCAT) Director Sells 4,500 Shares of Stock

Health Catalyst, Inc. (NASDAQ:HCAT) Director Duncan Gallagher sold 4,500 shares of the firm’s stock in a transaction on Monday, December 30th. The stock was sold at an average price of $6.93, for a total value of $31,185.00. Following the sale, the director now owns 69,938 shares in the company, valued at $484,670.34. This trade represents a 6.05 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Duncan Gallagher also recently made the following trade(s):

• On Monday, December 23rd, Duncan Gallagher sold 4,500 shares of Health Catalyst stock. The stock was sold at an average price of $6.98, for a total value of $31,410.00.

Health Catalyst Stock Up 1.1 %

Shares of NASDAQ:HCAT opened at $7.42 on Friday. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. Health Catalyst, Inc. has a 52-week low of $5.42 and a 52-week high of $11.41. The company has a 50 day moving average of $7.86 and a two-hundred day moving average of $7.49. The company has a market capitalization of $451.51 million, a price-to-earnings ratio of -5.50 and a beta of 1.31.

Health Catalyst (NASDAQ:HCAT) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The firm had revenue of $76.40 million during the quarter, compared to analyst estimates of $76.27 million. During the same period last year, the business earned ($0.22) EPS. The firm’s revenue was up 3.5% compared to the same quarter last year. As a group, analysts forecast that Health Catalyst, Inc. will post -0.33 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on HCAT shares. Piper Sandler restated an “overweight” rating and set a $12.00 price objective (up previously from $11.00) on shares of Health Catalyst in a report on Tuesday, November 26th. Royal Bank of Canada lifted their target price on Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a report on Thursday, November 7th. Cantor Fitzgerald restated an “overweight” rating and set a $16.00 price target on shares of Health Catalyst in a research note on Friday, October 4th. Evercore ISI lifted their price objective on Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a research note on Tuesday, October 8th. Finally, Stephens boosted their target price on Health Catalyst from $7.00 to $9.00 and gave the stock an “equal weight” rating in a report on Thursday, November 14th. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $11.59.

Institutional Trading of Health Catalyst

Large investors have recently bought and sold shares of the company. Principal Financial Group Inc. grew its position in shares of Health Catalyst by 6.9% during the second quarter. Principal Financial Group Inc. now owns 29,469 shares of the company’s stock worth $188,000 after buying an additional 1,907 shares in the last quarter. Harbor Capital Advisors Inc. grew its holdings in Health Catalyst by 21.3% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,764 shares of the company’s stock worth $96,000 after acquiring an additional 2,064 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Health Catalyst by 10.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,162 shares of the company’s stock worth $148,000 after purchasing an additional 2,164 shares during the last quarter. Creative Planning raised its stake in shares of Health Catalyst by 13.2% in the 3rd quarter. Creative Planning now owns 21,348 shares of the company’s stock valued at $174,000 after purchasing an additional 2,486 shares in the last quarter. Finally, Quarry LP lifted its position in shares of Health Catalyst by 59.4% during the second quarter. Quarry LP now owns 7,002 shares of the company’s stock worth $45,000 after purchasing an additional 2,610 shares during the last quarter. Institutional investors and hedge funds own 85.00% of the company’s stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.